Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (1): 67-73.

Previous Articles     Next Articles

Basic research of microRNA-34 for cancer therapy

LI Zheng1, XIANG Kai-ming2, PENG Shu-ping1, LI Gui-yuan1   

  1. 1Cancer Research Institute, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Central South University, Changsha 410078, Hunan,China;
    2Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China
  • Received:2013-04-29 Revised:2013-12-02 Online:2014-01-27 Published:2014-02-12

Abstract: MicroRNA-34(miR-34) inhibits many target genes involved in multiple oncogenic signaling pathways. The broad activity of miR-34 includes induction of cell cycle arrest and apoptosis, inhibition of tumor stem cells and metastasis and the anti-chemoresistance. There are increasing evidence suggesting that miR-34 plays a crucial role in cancer diseases and may be a potential therapeutic target. This review summarizes the biological function and molecular mechanisms of the miR-34 family, pharmacologies in animal tumor models, and reveals the possibility of miR-34 replacement therapy for the clinical treatment of tumor.

Key words: MicroRNA-34, Tumor, Gene therapy

CLC Number: